Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon2 and 38 bp deletion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-E2F3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
E2F3 also known by its alternate name E2F transcription factor 3 functions as a member of the E2F family of transcription factors which are important for the regulation of the cell cycle. This protein possesses a molecular mass of approximately 55 kDa. E2F3 is expressed in various tissues with significant expression in proliferative cells. It plays a critical role in transcription activation binding with DNA and regulating genes necessary for cell cycle progression especially during the transition from the G1 to the S phase.
Biological function summary
E2F3 forms part of the E2F/DP protein complex which controls cell cycle entry and progression. Its activity facilitates the transcription of genes essential for DNA replication and synthesis. Through its interaction with retinoblastoma proteins specifically pRB and p107 E2F3 modulates cellular proliferation. This regulation is vital for maintaining normal cellular functions and growth ensuring proper cell cycle checkpoints are upheld.
Pathways
E2F3 participates in the RB/E2F signaling pathway a major controller of cell proliferation and apoptosis. This pathway serves a critical function in the decision between cell cycle progression and arrest. E2F3 interacts with cyclins and cyclin-dependent kinases (CDKs) particularly CDK2 highlighting its role in the regulation of cell cycle dynamics. It also works alongside other E2F family members such as E2F1 and E2F2 to maintain the balance between cell growth and death.
E2F3 has implications in cancer most notably in bladder cancer due to its ability to drive uncontrolled cell proliferation when regulatory mechanisms fail. Overexpression of E2F3 often correlates with tumorigenesis serving as a potential biomarker for aggressive forms of cancer. The dysregulation of E2F3 in conjunction with pRB pathway alterations has links to retinoblastoma a rare eye cancer. In these contexts E2F3's activity becomes deregulated contributing to disease progression through its interaction with proteins like pRB and CDKs.
